Thursday, October 22, 2026

Venture Capital Pivots to AI Enterprise Deals as Crypto Growth Slows to 16% Despite 716M Users

Institutional investors are rotating capital from crypto—where growth decelerated to 16% YoY despite reaching 716M owners—into AI-driven enterprise software. Series B funding concentrated in automation platforms like Ivo and Nomagic, with specialist funds including Outlast and Cogito Capital targeting infrastructure plays. The shift mirrors Aswath Damodaran's thesis on Nvidia: AI represents disruptive technology justifying allocation rebalancing.

Venture Capital Pivots to AI Enterprise Deals as Crypto Growth Slows to 16% Despite 716M Users
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Crypto asset ownership hit 716 million users but growth slowed to 16% year-over-year, prompting venture capital firms to redeploy funds into AI-enabled enterprise solutions.

Series B rounds concentrated in enterprise automation startups including Ivo and Nomagic. Specialist funds like Outlast and Cogito Capital launched dedicated vehicles targeting AI infrastructure investments, marking a structural shift in risk capital deployment.

The rotation follows patterns NYU professor Aswath Damodaran outlined in recent Nvidia valuations: investors now view AI as disruptive technology rather than incremental tooling. This conviction drives allocation changes beyond typical sector cycling.

Crypto's deceleration stems from market saturation in developed economies and regulatory friction in emerging markets. The 716 million user base represents significant penetration, but monthly active usage metrics show plateauing engagement across major exchanges.

Private equity deployment into AI enterprise software jumped 43% quarter-over-quarter in late 2025, according to institutional LP reports. Funds cite margin expansion potential in business process automation versus crypto's compressed trading spreads.

Enterprise automation platforms attract capital because they replace legacy workflows with measurable productivity gains. Ivo's Series B pitch deck showed 37% reduction in operational costs for mid-market customers. Nomagic demonstrated 4.2x ROI within 18 months for manufacturing clients.

Infrastructure plays dominate AI allocations. Outlast's $340M fund targets compute layer investments, while Cogito Capital's $190M vehicle focuses on data pipeline tooling. Both funds structured longer hold periods—10-12 years versus traditional 7-year horizons—anticipating extended enterprise adoption cycles.

The divergence creates portfolio rebalancing across institutional LPs. University endowments reduced crypto exposure from 8% to 4.5% average allocation in 2025, redirecting capital to AI-linked private equity and venture strategies.

Corporate venture arms followed similar patterns. Strategic investors in fintech and payments reduced crypto seed investments by 62% year-over-year while increasing AI enterprise checks by 89%.

Market observers note the shift may accelerate if crypto user growth remains below 20% through 2026. Current trajectories suggest AI enterprise deals will capture 70% of growth-stage capital previously allocated to blockchain infrastructure.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score12 source documents12 with a live linkVerifiability: Strong
  1. [1]News articleYahoo Finance· January 6, 2026
    Charlie Munger once said you can ‘ease off the gas’ when you reach this money milestone, and Mark Tilbury agrees
  2. [2]News articleYahoo Finance· December 23, 2025
    Fan Tokens and the Road to 2026: Assessing the Opportunity
  3. [3]News articleYahoo Finance· January 27, 2026
    Star Equity (STRR) Q3 2025 Earnings Transcript
  4. [4]News articleYahoo Finance· January 27, 2026
    Star Equity (STRR) Q4 2024 Earnings Transcript
  5. [5]News articleNasdaq· January 6, 2026
    The Motley Fool Interviews NYU Professor Vasant Dhar: Thinking With Machines
  6. [6]News articleYahoo Finance· December 30, 2025
    12 investors dish on what 2026 will bring for climate tech
  7. [7]Press releaseGlobeNewswire· February 17, 2026
    13,000 strong: AIBC Eurasia 2026 sets the stage for a bigger 2027
  8. [8]Press releaseGlobeNewswire· February 17, 2026
    Basilea erzielt starke Ergebnisse im Geschäftsjahr 2025 und übertrifft Umsatz- und Betriebsgewinn-Guidance
  9. [9]News articleYahoo Finance· February 13, 2026
    DSV, 1166 - NOTICE OF ANNUAL GENERAL MEETING 2026
  10. [10]News articleYahoo Finance· February 19, 2026
    Renault Group demonstrates its resilience, the robustness of its strategy, and moves forward with confidence
  11. [11]News articleYahoo Finance· December 9, 2025
    Stock market today: Dow and S&P 500 slip, Nasdaq rises as Fed meeting kicks off, JOLTS data shows openings rose
  12. [12]Press releaseGlobeNewswire· February 18, 2026
    The Vita Coco Company Reports Fourth Quarter and Full Year 2025 Financial Results
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Crunch: Late-Stage Readouts and Regulatory Milestones Converge on the Ivonescimab PDUFA Date
October 2026 is dense with clinical and regulatory news. Phase 3 trials hit primary endpoints (ALOFT-IPF, RESTORE-3), long-term data came out (MIUDELLA at 6 years, QUILT-3.032), and the FDA accepted Roche's vamikibart BLA. Scholar Rock resubmitted its apitegromab MAA to the EMA. The next catalysts are ESMO 2026 (Oct 23) and the Nov 14 FDA PDUFA date for ivonescimab, followed by Maritime-1 primary completion in January 2027. The speculative QAIAx items (QIII pilot, microcities patent) are a weak, tangential thread with little financial substance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,426 source documents archived
Query this data → isubstrate.com